Please assess the completion status of the following clinical trial:

Trial Title: Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients with confirmed persistent or paroxysmal AF and suspected coronary artery disease who will undergo catheterization X-ray angiography~Exclusion Criteria:~1. Critically ill patients, patients on ventilators patients with hypotension, asthmatics, and other patients whose medical care or safety may be compromised from undergoing an MRI examination will be excluded.~2. Patients with claustrophobia will also be excluded since MRI is conducted in a closed environment.~3. Patients with contraindications to MRI (pacemaker, metal implants).~4. Pregnant subjects (or women who may become pregnant), minors, and prisoners will be excluded from this study.~5. Subjects are over 60 or have any suspicion of abnormal kidney function (a blood test to determine Glomerular filtration rate (GFR) will be performed prior to imaging. Subjects with GFR\<30 will be excluded from the study. This is standard practice for clinical scans in Radiology due to the extremely small but not negligible relationship between gadolinium contrast agent and nephrogenic systemic fibrosis in patients with severely impaired renal function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Regadenoson MRI (Type: EXPERIMENTAL): Participants with AF receiving regadenoson stress MRI, using Gadobenate dimeglumine

Based on this trial design, predict the completion outcome and termination type (if applicable).